A Trial Evaluating Concurrent Whole Brain Radiotherapy and Iniparib in Multiple Non Operable Brain Metastases (RAPIBE)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Recent pre-clinical and clinical data have indicated that BSI-201 does not possess characteristics typical of the PARP inhibitor class. Based on the results from in vitro and in vivo studies, this trial aims to evaluate the combination of BSI-201 concomitantly with radiotherapy in patients who present with multiple non operable brain metastases. As radiotherapy is a local treatment targeting only the tumor, and because the molecule BSI-201 has shown no major toxicity against tissues without DNA alterations, the proposed combination is expected to provide tumor-selective therapy and leading to a clinical benefit improvement.
Primary objective is to determine the recommended phase II dose (RP2D) and evaluate acute toxicity (CTC-AE v4.0 grading scale) of concurrent administration of whole brain radiotherapy (WBR) and a small molecule BSI-201 in non operable brain metastases.
| Condition | Intervention | Phase |
|---|---|---|
|
Brain Metastases |
Radiation: Radiation combined with iniparib (BSI-201) |
Phase 1 |
| Study Type: | Interventional |
| Study Design: | Endpoint Classification: Safety Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | A Phase I Trial Evaluating Concurrent Whole Brain Radiotherapy and Iniparib (BSI-201) in Multiple Non Operable Brain Metastases |
- To determine the Maximum Tolerated Dose (MTD) [ Time Frame: Until 12 week follow-up ] [ Designated as safety issue: Yes ]The MTD is defined as the dose level at which the Dose Limiting Toxicity (DLT) is observed in more than 20% of patients. The DLT is defined as: Any treatment-related toxicity CTC v4.0 ≥ grade 3(CTC-AE v4.0 grading scale)
- Rate of adverse events [ Time Frame: Until 6 month follow-up ] [ Designated as safety issue: Yes ]To evaluate toxicity later than 12 weeks after the end of radiotherapy and iniparib
- Quality of life [ Time Frame: At baseline, Week 1, Week 4, Week 6, Week 12 and Month 6 ] [ Designated as safety issue: No ]Quality of life will be assessed according to the EORTC QLQ-C30 and QLQ-BN20 questionnaires
- Cognitive functions [ Time Frame: At baseline, Week 1, Week 4, Week 6, Week 12 and Month 6 ] [ Designated as safety issue: No ]Cognitive functions will be assessed according to the MMS (Mini Mental State) questionnaire
- Objective response rate [ Time Frame: At 6 and 12 weeks after the end of radiotherapy ] [ Designated as safety issue: No ]Objective response rates (complete and partial response) will be evaluated by MRI according to the RECIST criteria (v1.1)
- Time to local progression [ Time Frame: 6 months ] [ Designated as safety issue: No ]Time to local progression will be measured from the start of treatment until the first date of objectively documented local progression.
- Local progression-free survival [ Time Frame: 6 months ] [ Designated as safety issue: No ]Local progression-free-survival will be measured from the start of treatment until the first date of objectively documented local progression or death.
| Estimated Enrollment: | 30 |
| Study Start Date: | September 2012 |
| Estimated Study Completion Date: | March 2014 |
| Estimated Primary Completion Date: | December 2013 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Experimental: Concurrent whole brain radiotherapy and iniparib |
Radiation: Radiation combined with iniparib (BSI-201)
Dose escalation of iniparib is implemented according to the CRML method. Three patients will be included at the first dose level (2.8 mg/kg). As long as no DLT is observed, escalation will proceed in cohorts of three patients at least included at the next dose levels (4, 5.6, 8, 11.2 mg/kg). Once a DLT is observed, the CRML will be activated and will be used until the MTD has been found or until six patients have been treated at the highest dose level (11.2 mg/kg). A dose level of 2.0 mg/kg (dose level -1) is included in case the first dose level at 2.8 mg/kg is found to be the MTD. Iniparib is given by iv infusion over 1 hour twice weekly. BSI 201 will start the week before the beginning of radiotherapy (W1) and will be continued during the entire irradiation (W2, W3, W4). It will be stopped after 8 injections. RT is delivered five days a week over 3 weeks (W2, W3, W4) up to a total dose of 37.5 Gy. Each fraction delivers 2.5 Gy by two opposed tangential fields. |
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Non operable brain metastases from any type of cancer (≥ 2)
- At least one measured brain target available ≥ 1 cm (T1-weighted sequences with contrast application MRI)
- No stereotaxie indication
- Any anterior treatments for systemic disease (any chemotherapy at any line) are accepted but have to be interrupted at least 15 days before and up to 30 days after the present protocol
- No extra-brain disease or stabilized since at least 1 month
- Aged ≥ 18 years old
- KPS > 70 (RPS class I or II)
- Adequate bone marrow function: WBC ≥ 3.5 x 109/L, ANC ≥ 1.5 x 109/L, Platelets ≥ LLN, Hb > 10g/dL,
- Adequate renal function: serum creatinine ≤ 1.5 × ULN and blood urea nitrogen ≤ 25 mg/dL
- Male or female patient using adequate contraceptive method
- Women of childbearing potential must have a negative serum or urine pregnancy test within 3 days prior to the start of treatment
- Informed and signed consent
- Able to be followed according to the terms of the protocol
- Affiliated to the French National social security
Exclusion Criteria:
- Anterior treatment for brain metastases (surgery, radiosurgery, stereotaxie)
- Leptomeningeal metastases
- Inclusion in another protocol within 30 days
- Brain metastases with severe intracranial hypertension clinical signs
- Other cancer except the known primary tumor or in situ cervix cancer or basocellular carcinoma
Contacts and Locations| Contact: Jean-Pierre Bleuse, MD | +33 4 67 61 23 44 | Jean-Pierre.Bleuse@montpellier.unicancer.fr |
| France | |
| CRLC Val d'Aurelle-Paul Lamarque | Recruiting |
| Montpellier, France, 34298 | |
| Contact: David Azria, MD, PhD + 33 4 67 61 85 79 David.Azria@montpellier.unicancer.fr | |
| Principal Investigator: David Azria, Pr | |
| AP-HP Hôpital Saint-Louis | Recruiting |
| Paris, France | |
| Contact: Christophe Hennequin, Pr | |
| Principal Investigator: Christophe Hennequin, Pr | |
| Institut Gustave-Roussy | Recruiting |
| Villejuif, France | |
| Contact: Céline Bourgier, Dr | |
| Principal Investigator: Céline Bourgier, Dr | |
| Principal Investigator: | David Azria, MD, PhD | CRLC Val d'Aurelle-Paul Lamarque |
More Information
No publications provided
| Responsible Party: | Centre Val d'Aurelle - Paul Lamarque |
| ClinicalTrials.gov Identifier: | NCT01551680 History of Changes |
| Other Study ID Numbers: | RAPIBE, 2011-003772-36 |
| Study First Received: | February 10, 2012 |
| Last Updated: | October 18, 2012 |
| Health Authority: | France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis) |
Additional relevant MeSH terms:
|
Neoplasm Metastasis Neoplasms, Second Primary Brain Neoplasms Neoplastic Processes Neoplasms Pathologic Processes |
Central Nervous System Neoplasms Nervous System Neoplasms Neoplasms by Site Brain Diseases Central Nervous System Diseases Nervous System Diseases |
ClinicalTrials.gov processed this record on May 19, 2013